Physician profile
Paula Cusi
NPI 1295386563
$9,319.86
in general payments reported to CMS, 2019-2025
29 companies · $1,471 in 2025
The $1,471 reported for 2025 was more than what 87% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,531 · 2022: $1,469 · 2023: $2,371 · 2024: $2,478 · 2025: $1,471.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,501 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,613 · Education: $205.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,501.28 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,613.25 |
| Education | $205.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,258.86 | 2021-2025 | |
| Genzyme Corporation | $1,180.57 | 2021-2025 | |
| Incyte Corporation | $1,074.55 | 2021-2025 | Opzelura |
| E.R. Squibb & Sons, L.L.C. | $523.80 | 2022-2024 | Sotyktu |
| Regeneron Healthcare Solutions, INC. | $510.70 | 2021-2025 | Dupixent, Libtayo |
| Novartis Pharmaceuticals Corporation | $358.02 | 2021-2024 | |
| Sun Pharmaceutical Industries INC. | $285.20 | 2021-2024 | Ilumya, Winlevi |
| Lilly USA, LLC | $259.31 | 2021-2024 | Olumiant, Taltz |
| Pfizer INC. | $226.30 | 2021-2024 | |
| Janssen Biotech, INC. | $215.40 | 2021-2024 | Tremfya |
| Dermavant Sciences, INC. | $203.39 | 2023-2024 | Vtama |
| Amgen INC. | $199.40 | 2021-2024 | Otezla |
| Galderma Laboratories, L.P. | $181.07 | 2021-2024 | Dysport |
| Ucb, INC. | $164.05 | 2021-2025 | Cimzia, Bimzelx |
| Sanofi-Aventis U.S. LLC | $159.98 | 2021-2025 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $117.60 | 2021 | |
| Arcutis Biotherapeutics, INC. | $86.64 | 2024 | Zoryve |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $50.51 | 2021 | |
| Dermira, INC. | $35.57 | 2021 | |
| Almirall LLC | $33.66 | 2021-2022 | |
| Leo Pharma INC. | $33.42 | 2021 | |
| Genentech USA, INC. | $29.24 | 2021 | |
| Bioventus LLC | $22.07 | 2022 | |
| Merz North America, INC. | $21.81 | 2022 | |
| Mayne Pharma Commercial LLC | $20.40 | 2021 | |
| Vyne Pharmaceuticals INC. | $19.23 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.98 | 2023 | Spevigo |
| Medtronic, INC. | $16.85 | 2023 | Venaseal |
| Organon LLC | $13.28 | 2025 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paula Cusi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.